

## ABBREVIATED CURRICULUM VITAE

### PERSONAL INFORMATION

**First Name:** Eleni  
**Last Name:** Kapsali  
**Year of Birth:** 19th June 1968

### HOSPITAL ADDRESS (Current Position)

**Hospital:** University Hospital of Ioannina  
**Clinic /Department:** Department of Hematology  
**Address:** Stavrou Niarchou Avenue  
**Postal Code:** 45 500  
**City:** Ioannina  
**Country:** Greece  
**Telephone Number:** +30 26510 99655      **Fax Number:** +30 26510 99655  
**Mobile:** +30 693 733 4216  
**E-mail Address:** [elkapsali@gmail.com](mailto:elkapsali@gmail.com), ekapsali@uoi.gr

### ACADEMIC QUALIFICATIONS

Degree and / or Certification	Institution	Year of Completion
PhD	Medical School, University of Ioannina, Greece Thesis in "Prognostic Factors in Chronic Lymphocytic Leukemia"	2002
Medical Degree	Medical School, University of Ioannina, Greece	Mar/1993

### PROFESSIONAL EXPERIENCE

Position held	Name of Department / Institution	Start Date – End Date
Director of Department of Hematology	University Hospital of Ioannina	September 2016 – continue
Assistant Professor of Hematology	University of Ioannina, School of Medicine	July 2011 – continue
Lecturer of Hematology,	University of Ioannina, School of Medicine	September 2005 – July 2011
Trainee in Hematology	University Hospital of Ioannina, Division of Internal Medicine, Hematology Unit	September 1997 – September 2001

### PROFESSIONAL SOCIETY MEMBERSHIPS

1. European Hematology Association
2. Hellenic Association of Hematology.
3. Hellenic Flow Cytometry Association.
4. American Society of Hematology

### FOREIGN LANGUAGES

Language	Fluency / Degree
English	Certificate of Proficiency-University of Cambridge (1994)
French	Sorbonne II.

## GOOD CLINICAL PRACTICE (GCP)

---

<b>Duration:</b>	1 day
<b>Title / Content:</b>	Good Clinical practice
<b>Provider:</b>	GlaxoSmithKline
	<b>Physically</b> x
<b>Training Type:</b>	<b>Present:</b> <b>Online training:</b>
<b>Date of Training Certificate:</b>	23/Aug/2012

---

<b>Duration:</b>	2 Hours
<b>Title / Content:</b>	Good Clinical Practice
<b>Provider:</b>	The Global Health Network
<b>Training Type:</b>	<b>Physically Present:</b> <b>Online training: x</b>
<b>Date of Training Certificate:</b>	10/Oct/2016
<b>Date of Training Certificate</b>	9/10/2017
<b>Date of Training Certificate</b>	14/4/2019
	12/3/2021

---

## ADDITIONAL TRAINING

<b>Completion Date</b>	<b>Title / Content:</b>
<b>9/2000- 3/2001</b>	Six months training in St Georges ` Hospital , Hematology Department , London UK, Professor E.C.Gordon-Smith

---

## CLINICAL TRIAL EXPERIENCE

### Role: Principal Investigator

- a. A phase 3, open label trial of lenalidomide /dexamethasone with or without elotuzumab in subjects with previously untreated Multiple Myeloma,Sponsor: Bristol-Myers Squibb
- b. A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients ≥ 65 years with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy,Sponsor: Boehringer Ingelheim
- c. A prospective non-interventional post-authorization safety study (PASS), designed as a disease registry of patients with transfusion dependent IPSS low or intermediate-1 risk myelodysplastic syndromes (MDS) and isolated del(5q),Sponsor: Celgene
- d. A multicentre, open label, single arm, phase IIIb, international study evaluating the safety of Obinutuzumab alone or in combination with chemotherapy in patients with previously untreated or relapsed/refractory chronic lymphocytic leukemia,Sponsor: Hoffmann-La Roche
- e. A Randomized, Controlled, Double-Blind Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of GP2013 plus CVP vs. MabThera® plus CVP, Followed by GP2013 or MabThera® Maintenance Therapy in Patients with Previously Untreated, Advanced Stage Follicular Lymphoma,Sponsor: Sandoz
- f. A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation, Sponsor:Takeda
- g. A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHTMM study, , Sponsor:Takeda
- h. A randomized, double-blind study evaluating the efficacy, safety and immunogenicity of ABP 798 compared with Rituximab in subjects with CD20 positive B-Cell Non-Hodgkin Lymphoma (NHL), Phase: 3, Sponsor : Amgen Inc.

- i. A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma, Sponsor: Acerta Pharma
- j. A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia, Sponsor : : Takeda
- k. A phase 2/3 randomized , open-label study comparing oral ixazomib/dexamethasone and oral pomalidomide/dexamethasone in relapsed and/or refractory Multiple Myeloma, Sponsor: Takeda
- l. Management of Chronic Myeloid Leukemia (CML) with dasatinib in a Real-world setting, Sponsor: Hellenic Society of Haematology
- m. Multicenter, non-interventional, observational study to collect data on the safety and tolerability of nilotinib in everyday clinical practice as per the SmPC guidance in patients with newly diagnosed Chronic Myeloid Leukemia (CML) in CP or CML in CP or accelerated phase who are resistant/intolerant to prior therapy, Sponsor : Novartis
- n. An observational study of the impact on the quality of life, effectiveness and safety of ruxolitinib in patients with primary or secondary post-polycythemia vera or post-essential thrombocythemia myelofibrosis: The "ESCAPE" study, Sponsor : Novartis
- o. A retrospective chart review and a prospective study of the pomalidomide plus low dose dexamethasone efficacy in relapsed/refractory Multiple Myeloma patients under real-life conditions, Sponsor : Genesis Pharma SA
- p. A nationwide, epidemiological, retrospective cross-sectional study to capture the real-world complication burden, associated hospital resource utilization, and disease management paradigms and to identify determinants of complications in transfusion-dependent Beta-Thalassemia adults in Greece, Sponsor :Genesis Pharma SA
- q. A multi-center, randomized, double blind, placebo-controlled clinical trial of deferasirox in patients with myelodysplastic syndromes (low/int-1 risk) and transfusional iron overload (TELESTO) , Sponsor : Novartis
- r. A Multicenter, Randomised, Double-blind, Placebo-controlled Study of Darbepoetin alfa for the Treatment of Anaemic Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS),Sponsor:Amgen
- s. A comparative, randomized, parallel-group, multi-centre, phase iiib study to investigate the efficacy of subcutaneous (SC) rituximab versus intravenous (IV) rituximab both in combination with chop (r-chop) in previously untreated patients with cd20 positive diffuse large b-cell lymphoma (DLBCL),Sponsor: Hoffmann-La Roche
- t. Prospective, Observational, Cohort study of Lonquex• (Lipegfilgrastim) used in clinical practice for the prophylactic treatment of chemotherapy-induced neutropenia in adult patients with solid or haematological cancer receiving myelosuppressive chemotherapy,Sponsor:TEVA
- u. A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared with Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of Treatment,Sponsor:Novartis

**Role: Sub-Investigator**

- a. Clinical outcomes of relapse/refractory Chronic Lymphocytic Leukemia ( R/R CLL) patients treated with venetoclax in routine clinical settings in Greece, Sponsor : AbbVie Pharmaceuticals S.A, PI :Assistant Prof. Eleftheria Hatzimichael
- b. A phase 3, double-blind, multicentric, randomized, placebo-controlled study to assess the efficacy, safety and tolerability of itraconazole-drypowder for inhalation for the prevention of invasive mould disease inpatients with Acute Leukemia and Neutropenia,Sponsor: Laboratoires SMB S.A.,PI: Assistant Prof. Eleftheria Hatzimichael

- c. A retrospective analysis of clinical outcomes of relapse/refractory Chronic Lymphocytic Leukemia (R/R CLL) patients treated with venetoclax: Retrospective analysis from Greece, Sponsor:AbbVie, PI: Assistant Prof. Eleftheria Hatzimichael

## MOST RECENT PUBLICATIONS

Publication Date	Title
2021	<p><b>Am J Cardiovasc Dis 2021;11(3): 391-397</b>            Evolution of electrocardiographic abnormalities and arrhythmias in adult patients with beta-thalaseemia major during a short- term follow-up.            Marios Kolios, Tong Liu, Antonios P Vlahos, <u>Eleni Kapsali</u>, Panagiotis Korantzopoulos</p>
	<p><b>Int J Lab Hematol 2021; 00:1-3</b>            Leishmaniasis mimicking multiple myeloma            Ioannis Papakostantinou, Epameinondas Koumpis, Eugenia Fytsili, Aikaterini Panteli, Haralampos Milionis, Alexandra Papoudou-Bai, <u>Eleni Kapsali</u>, Eleftheria Hatzimichael</p>
	<p><b>Pathology-Research and Practice 225 (2021) 153567</b>            CD56 expression in multiple myeloma : Correlation with poor prognostic markers but no effect on outcome            Epameinondas Koumpis, Iliana Tassi, Theodora Malea, Kostantina Papathanasiou, Ioannis Papakostantinou, Anastasia Serpanou, Evangelos Tsolas, <u>Eleni Kapsali</u>, Theodoros P.Vassilakopoulos, Alexnadra Papoudou- Bai, Eleftheria Hatzimichael</p>
	<p><b>.Rifampicin-Induced Thromocytopenia: A Case Report ans Short Review of the Literature.</b>            Epameinondas Koumpis, Kostantina Papathanasiou, Ioannis Papakostantinou, Iliana Tassi, Anastasia Serpanou, <u>Eleni Kapsali</u>, Eleftheria Hatzimichael</p>
	<p><b>.In vivo 35: 1951-1957(2021)</b>  <b>Paraneoplastic Intrahepatic Cholestasis in Sypradiaphragmatic Classical Hodgkin Lymphoma Successfully Treated With Brentuximab Vedotin: A Case Report and Review of the Literature</b>            Ioannis Papakostantinou, Maria Ksomidou, Kostantina Papathanasiou, Epameinondas Koumpis, <u>Eleni Kapsali</u>, Haralampos Milionis, Theodoros Vassilakopoulos, Alexandra Papoudou-Bai, Eleftheria Hatzimichael.</p>
	<p><b>Thrombosis update 3 (2021) 10043</b>  <b>Real world data of thrombotic micrangiopathic management : The key role of ADAMTS13 activity and complement testing.</b>            Eleni Gagriilaki, Evdoxia-Evangelia Koranou, Thomas Chatziconastantinou, Christina Kalpadaki, Nikoleta Printza, Maria Ximeri, Anna Christoforidou, George Karavalakis, Maria Kaliou, Vassiliki Kalaitzidou, Iliana Tassi, Maria Tzellou, Tasoula Touloumelidou, Apostolia Papalexandri, Maria Papathanasiou, Antonia Syrigou, Anna Kioumi, Maria Liga, Georgia Kaiafa, Alexandros</p>

	Spyridonidis, <u>Eleni Kapsali</u> , Kostantinos Kolios, Eudokia Mandala, Efthymia Vlachaki, Panagiotis Tsirigotis, Eleni Papadaki, Chrysavgi Lalagiani, Ioanna Sakellari, Achilles Anagnostopoulos
<b>2019</b>	<b>Case Rep Dermatol Med 2019;2019:3730915</b> CD5-Positive Primary Cutaneous Diffuse Large B-Cell Lymphoma-Leg Type A.Papoudou-Bai, L.Marinos, A.Vassou, E.Kapsali, P.Kanavaros
<b>2018</b>	<b>Turk J Hematolo. 2018 Nov;35(4):308-309</b> Simultaneous Presence of Follicular ,Diffuse Large B-Cell Lymphoma and Hodgkin –Like Lymphoma A.Papoudou-Bai, L.Marinos, K.Papathanasiou,P.Kanavaros, E.Kapsali  <b>Case Rep Dermatol Med 2018;2018:2874012</b> Sustained Regression of Hydroxycardamide Induced Actinic Keratoses after Switching to Anagrelide G.Gaitanis,D.Gougopoulou,E.Kapsali,I.Bassukas
<b>2017</b>	<b>Hemoglobin 2017 May, 41(3);223-224,</b> Rivaroxaban use in Patients with Hemoglobinopathies . Apostolou C, Klonizakis P, Mainou M,Kapsali E, Kafantari K,Kotsiafti A, Vetsiou E,Valalopoulou S,Vlachaki E.  <b>Case Rep Hematol 2017;2017:2861596</b> Plasmablastic Lymphoma with Coexistence of Chronic Lymphocytic Leukemia in an immunocompetent Patient: A Case Report and Mini – Review E.Hatzimichael, K.Papathanasiou, I. Zerdes, S.Flindris, A.Papoudou-Bai, E.Kapsali
<b>2016</b>	<b>Int J Cardiol.2016 Oct 15;221:932-6</b> Electrocardiographic abnormalities and arrhythmic risk markers in adult patients with beta thalassemia major Kolios M, Korantzopoulos P, Vlahos AP, Kapsali E, Briasoulis E, Goudevenos JA  <b>Acta Haematol. 2016;135(2):124-30</b> Higher Serum Ferritin Levels Correlate with an Increased Risk of Cutaneous Morbidity in Adult Patients with $\beta$ Thalassemia: A single-center Retrospective Study. Skandalis K, Vlachos C, Pliakou X, Gaitanis G, Kapsali E, Basioukas
<b>2014</b>	<b>Research 2014:1:683</b> Incipient multiple myeloma presenting as purpura. I.Basioukas , E.Kapsali,A.Zioga, I.Alexis, G.Gaitanis

2010	<p><b>Ann Pharmacother. 2010 Oct;44(10):1677-80</b>          Brucellosis-induced autoimmune hemolytic anemia treated with rituximab          Bourantas LK, Pappas G, Kapsali E, Gougopoulou D, Papamichail D, Bourantas KL</p>
2006	<p><b>Clin Lab Haem 2006;28:416-418.</b>          Spontaneous splenic haematoma in a multiple myeloma patient receiving pegfilgrastim support.          E. Hatzimichael, L. Benetatos, J. Stebbing, E. Kapsali,, S. Panayiotopoulou, K.L. Bourantas</p>
2006	<p><b>Acta Haematologica September, 2006.</b>          Recombinant human erythropoietin for the treatment of anemia in patients with Chronic Idiopathic myelofibrosis.          St. Tsiara, A. Chaidos, L.K. Bourantas, E. Kapsali, K.L. Bourantas.</p>
2004	<p><b>Haema 2004;7(13):340-344.</b>          Pentostatin administration in patients with resistant/relapsing chronic lymphocytic leukemia.          St. Tsiara, A. Chaidos, L. Christou, M. Tzilianos, E. Kapsali, K.L. Bourantas.</p>
2004	<p><b>J Exp Clin Cancer Res, 23, 1, 2004.</b>          Successful treatment of Refractory Anemia with a Combination Regimen Containing Recombinant Human Erythropoietin, Low-Dose methylprednisolone and Nandrolme.          St. Tsiara, A. Chaidos, M. Gouva, L. Christou, K. Panteli, E. Kapsali, K.L. Bourantas.</p>

**Signature: ELENI KAPSALI**

**Date:3/11/2021**